Aggressive squamous cell carcinoma of the renal pelvis

Niger J Clin Pract. 2019 Apr;22(4):588-590. doi: 10.4103/njcp.njcp_434_18.

Abstract

Squamous cell carcinoma (SCC) of the renal pelvis is a particularly rare tumor that accounts for a minor portion of renal malignancies and is aggressive with an unfavorable prognosis. It is usually diagnosed after surgery and at advanced stages as it does not possess specific clinical and radiological properties. The pathological examination of a 38-year-old female patient who had undergone nephrectomy due to a nonfunctioning right kidney caused by long-standing staghorn calculus revealed moderately differentiated renal pelvis SCC invading the renal parenchyma. The patient who experienced severe lumbar pain in the second postoperative month presented lymphadenopathy, which could not be detected with ultrasonography but was diagnosed with 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18FDG PET/CT). The patient received systemic treatment following the early diagnosis and survived past the average survival time. It was concluded that in cases where SCC was diagnosed after nephrectomy, investigating metastasis with 18FDG PET/CT and initiating early systemic treatment in the presence of metastasis could contribute to survival.

Keywords: 18F-fluorodeoxyglucose positron emission tomography/computed tomography; renal pelvis; squamous cell carcinoma; staghorn calculus.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Carcinoma, Renal Cell / pathology*
  • Carcinoma, Renal Cell / surgery
  • Carcinoma, Squamous Cell / pathology*
  • Carcinoma, Squamous Cell / surgery
  • Fatal Outcome
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Kidney Neoplasms / pathology*
  • Kidney Neoplasms / surgery
  • Kidney Pelvis / diagnostic imaging*
  • Kidney Pelvis / pathology
  • Lymphadenopathy
  • Male
  • Neoplasm Staging
  • Nephrectomy
  • Positron Emission Tomography Computed Tomography / methods*
  • Radiopharmaceuticals

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18